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Abstract
Background: Colorectal cancer (CRC) screening reduces CRC incidence and mortality. However, current screening
methods are either hampered by invasiveness or suboptimal performance, limiting their effectiveness as primary
screening methods. To aid in the development of a non-invasive screening test with improved sensitivity and
specificity, we have initiated a prospective biomarker study (CRCbiome), nested within a large randomized CRC
screening trial in Norway. We aim to develop a microbiome-based classification algorithm to identify advanced
colorectal lesions in screening participants testing positive for an immunochemical fecal occult blood test (FIT). We
will also examine interactions with host factors, diet, lifestyle and prescription drugs. The prospective nature of the
study also enables the analysis of changes in the gut microbiome following the removal of precancerous lesions.
Methods: The CRCbiome study recruits participants enrolled in the Bowel Cancer Screening in Norway (BCSN)
study, a randomized trial initiated in 2012 comparing once-only sigmoidoscopy to repeated biennial FIT, where
women and men aged 50–74 years at study entry are invited to participate. Since 2017, participants randomized to
FIT screening with a positive test result have been invited to join the CRCbiome study. Self-reported diet, lifestyle
and demographic data are collected prior to colonoscopy after the positive FIT-test (baseline). Screening data,
including colonoscopy findings are obtained from the BCSN database. Fecal samples for gut microbiome analyses
are collected both before and 2 and 12 months after colonoscopy. Samples are analyzed using metagenome
sequencing, with taxonomy profiles, and gene and pathway content as primary measures. CRCbiome data will also
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be linked to national registries to obtain information on prescription histories and cancer relevant outcomes
occurring during the 10 year follow-up period.
Discussion: The CRCbiome study will increase our understanding of how the gut microbiome, in combination with
lifestyle and environmental factors, influences the early stages of colorectal carcinogenesis. This knowledge will be
crucial to develop microbiome-based screening tools for CRC. By evaluating biomarker performance in a screening
setting, using samples from the target population, the generalizability of the findings to future screening cohorts is
likely to be high.
Trial registration: ClinicalTrials.gov Identifier: NCT01538550.
Keywords: Diet, Lifestyle, Prescription drugs, Gut microbiome, Metagenomics sequencing, Biomarkers, Screening,
FIT, iFOBT, Colonoscopy, Adenoma, Colorectal cancer, Advanced neoplasia
Background
Colorectal cancer (CRC) is a major global health burden,
accounting for nearly 10% of all cancers diagnosed and
cancer-related deaths each year [1]. Although a decline
in the age-standardized mortality rate has been observed
over the past two to three decades in many countries
[2–4], death rates remain high, particularly when diag-
nosed at later stages (5-year survival rate of 13% for
metastatic disease compared to 90% when diagnosed at
a localized stage) [1, 5]. The significant contribution to
global cancer deaths, together with the worrying rise in
incidence rates seen globally [3], especially the recent in-
crease among younger age groups [6, 7], highlights the
need for widespread prevention strategies that are both
effective and feasible on a large-scale basis.
There are two major precursor lesions of CRC: aden-
omatous polyps, accounting for the majority of cases,
and serrated lesions, estimated to underlie up to 30% of
CRC [8]. The progression of precursor lesions to CRC is
a long-term process, spanning a period of 10–15 years
for most lesions [9]. During this long latency period,
most cancers develop asymptomatically, making them
difficult to detect at a preclinical stage. Therefore, inter-
national guidelines recommend screening, with the aim
of detection and removal of precancerous lesions to pre-
vent cancer from occurring, or to detect cancer at the
earliest stage possible [10–13].
Screening has been shown to reduce both CRC inci-
dence [14–17] and mortality [14–21] in randomized con-
trolled trials, even though current screening methods have
known limitations [22]. At present, the most commonly
used screening method is the fecal immunochemical test
(FIT) for occult blood, having mostly replaced the less
sensitive guaiac-based fecal occult blood test (gFOBT)
[23]. Despite being more sensitive, performance character-
istics are still suboptimal with regards to sensitivity and
specificity, resulting in both missed neoplasms and un-
necessary colonoscopy referrals [22]. Of particular con-
cern has been the limited performance in detecting
precancerous lesions, representing a missed opportunity
given the great potential for cancer prevention following
removal of these lesions. There is also evidence that
current screening methods perform worse for right-sided
tumors, compared to left-sided ones [24], as well as in
women compared to men [25, 26]. Thus, there is a re-
quirement for screening methods and tools with improved
performance for the entire screening population.
Both observational and experimental evidence point to
an important role of the gut microbiome in development
and progression of CRC [27]. Numerous studies have
demonstrated differences in the gut microbiome of
tumor and adjacent non-tumor tissue [28, 29], as well as
in stool samples from CRC patients and healthy controls
[30–38]. Typically, the presence of a colorectal tumor
has been associated with enrichment of pathogenic bac-
terial species, such as F. nucleatum, E. coli and B. fragi-
lis, and depletion of potentially protective bacteria (e.g.
producers of short chain fatty acids (SCFAs)) [27]. Al-
though less studied, there are reports indicating that
subjects with precancerous lesions display shifts in their
microbial profiles [30, 33, 39], suggesting the presence of
microbial changes at early stages of colorectal
carcinogenesis.
The gut microbiome is heavily influenced by the envir-
onment [40]. Established risk factors for CRC, such as
excess body weight, physical inactivity and a Western
dietary pattern (typically high in red and processed meat
and low in whole grains and dietary fiber) and protective
factors, such as dairy products and use of certain medi-
cations (e.g. aspirin/NSAIDs and metformin) are sug-
gested to modify the gut microbiome [41]. At the same
time, accumulating evidence indicates that modifications
of the gut microbiome may allow environmental risk
factors to induce malignant transformation [42, 43]. This
highlights the complex relationship between the envir-
onment and the microbiome in the etiology of CRC.
The connection between a potentially pathogenic gut
microbiome and CRC has resulted in a growing interest
in the use of gut microbial biomarkers as screening tests
for early detection of precancerous and cancerous
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lesions. Several studies have shown that combining
microbiome data with the results of established screen-
ing methods, such as gFOBT or FIT, substantially in-
crease the ability to classify groups of individuals
with healthy colons, adenoma and CRC [30, 33, 34].
Two recent meta-analyses of metagenome data
showed that both taxonomic and functional gut mi-
crobial profiles predicted CRC at time of diagnosis
with high accuracy [44, 45].
Although results from previous biomarker studies are
promising, no microbial biomarkers are currently used
in national screening programs. In order to advance the
utility of the gut microbiome in screening, additional
data from prospective studies are needed.
Objectives
The primary aim of the CRCbiome study is to develop a
classification algorithm for identification of advanced
colorectal lesions based on the screened individuals’ gut
metagenome, demographics and lifestyle. Secondary
aims are to provide a deeper understanding of how the
gut microbiome evolves prior to a cancer diagnosis, as
well as its interactions with host, lifestyle and environ-
mental factors:
I. Identification of associations of the gut microbiome
with advanced colorectal lesions, defined as
presence of advanced adenomas, advanced serrated
lesions or CRC, at baseline
II. Examination of interactions of the gut microbiome
with host factors, diet, lifestyle and medication use
on risk of advanced colorectal lesions at baseline
III. Description of changes in the gut microbiome
following removal of precursor lesions of CRC
Long-term outcomes (i.e. incidence and mortality of
advanced colorectal lesions) will be examined by means
of passive follow-up using data from the national regis-
tries. The outcome assessment will be aligned with the
10 year follow-up of the Bowel Cancer Screening in




The CRCbiome study is a prospective cohort study
nested within the BCSN trial, which is a pilot for a na-
tional screening program, organized by the Cancer
Registry of Norway. The BCSN study is designed as a
randomized trial comparing once-only sigmoidoscopy
with FIT tests every two years for a maximum of four
rounds [46]. The trial was started in 2012, with follow-
up FIT rounds scheduled to be completed in 2024. Par-
ticipants randomized to the FIT group who test positive
(i.e. hemoglobin > 15 mcg/g feces), are referred for
follow-up colonoscopy at their local screening center.
Neoplastic lesions detected as part of the screening
examination are removed during colonoscopy or elective
surgery, if necessary. Biennial FIT testing is discontinued
for those having undergone colonoscopy following a
positive FIT test.
The CRCbiome study recruits participants from the
BCSN trial who receive a positive FIT test. FIT positive
participants are selected since they are referred to
follow-up colonoscopies in line with the BCSN study
protocol and will have detailed clinicopathological infor-
mation. Conversely, as no diagnostic information is
available for those with a negative FIT test, these are not
included in the CRCbiome study. Of note, as recruit-
ment for the CRCbiome study started five years after
commencement of the BCSN trial, those with positive
FIT findings in the first and initial part of the second
round of screening in the BCSN were not invited. Even
so, due to incomplete participation in the first round of
FIT testing, 10% of the CRCbiome participants had their
inclusion sample as their first screening test.
Participants are invited to the CRCbiome study prior
to their colonoscopy examination. The invitation in-
cludes an information letter and two questionnaires (fur-
ther details given below). FIT-positive fecal samples
from the BCSN are retrieved following enrolment and
represent the baseline sample of the CRCbiome study.
Participants are thereafter contacted 2 and 12months
after colonoscopy for collection of follow-up fecal sam-
ples using the same sampling method. Fecal samples are
processed for microbiome analysis as they become avail-
able to the project.
Based on the colonoscopy examination, participants
are categorized into diagnostic groups ranging from no
pathological findings to presence of advanced lesions
and CRC. The groups selected for analyses will vary de-
pending on aim (see Outcome variables for a complete
description of outcomes).
Data collected in the CRCbiome study will be linked
to national registries, including the Norwegian Prescrip-
tion Database [47] and the Cancer Registry of Norway
[48]. An overview of the study design is shown in Fig. 1.
The design and handling of data in the CRCbiome study
is in accordance with the STROBE guidelines for obser-
vational and metagenomics studies [49–51].
Participants and eligibility
The BCSN trial includes 139,291 women and men aged
50–74 years in 2012, living in South-East Norway. Of
these, 70,096 have been randomized to FIT screening.
So far, the cumulative participation rate for the first
three FIT rounds has been 68% [46]. All screening par-
ticipants with a positive FIT test are eligible for the
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CRCbiome study. Recruitment for the CRCbiome study
started in 2017, and will continue until a minimum of
2700 participants have been invited. So far, 2426 have
been invited and 1413 (58%) have agreed to participate.
With the current participation rate, we expect recruit-
ment to be completed by March 2021 with a final num-
ber of participants of about 1600 (see below for the
sample size considerations). Recruitment bias will be
evaluated by comparing key characteristics of the in-
cluded participants, such as age, sex and BMI, with those
of the BCSN.
The main inclusion and exclusion criteria for the
BCSN trial and the CRCbiome study are listed in
Table 1.
Recruitment of participants
Eligible subjects are invited after being informed about
their positive FIT test and a colonoscopy appointment
has been scheduled. Invitations to the CRCbiome study,
including the two questionnaires, are sent out by mail a
minimum of four days prior to the colonoscopy. Return-
ing at least one of the two questionnaires is regarded as
a consent to the study, and includes permission to col-
lect, analyze and store fecal samples, and to retrieve in-
formation from questionnaires and health registries.
Both the BCSN trial and the CRCbiome study have
been approved by the Regional Committee for Medical
Research Ethics in South East Norway (Approval no.:
2011/1272 and 63,148, respectively). The BCSN is also
registered at clinicaltrials.gov (Clinical Trial (NCT) no.:
01538550).
Outcome variables
For the first two aims, the outcome variable will be de-
fined based on the colonoscopy result. Participants will
be grouped into four main categories: no confirmed
Fig. 1 Flowchart of the CRCbiome study, nested within the BCSN. Abbreviations: BCSN, Bowel Cancer Screening in Norway; CRN, Cancer Registry
of Norway; FIT, fecal immunochemical test; FU, follow-up; NorPD, Norwegian Prescription Database
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neoplastic findings (Group 1); non-advanced lesions
(Group 2); advanced lesions (Group 3); and CRC (Group
4) (Table 2). The advanced lesions group consists of
both advanced adenomas (any adenoma with villous
histology, high-grade dysplasia or polyp size greater than
or equal to 10 mm) and advanced serrated lesions (any
serrated lesion with size ≥10 mm or dysplasia). In
addition to separating by stage of the carcinogenic
process, we may further subdivide lesions by clinicopath-
ological features, including histopathological subtype
(e.g. adenomas versus serrated lesions) and site of occur-
rence (proximal versus distal colon). Also of interest is
the potential for distinct roles of environmental factors
and the gut microbiome in the two main pathways of
colorectal carcinogenesis: the adenoma-carcinoma path-
way, and the serrated carcinoma pathway.
For the third aim, the outcome variable will be defined
based on the metagenome data. We will monitor several
aspects of the gut microbiome to describe the presence
of bacterial strains and the functional potential in paired
samples during re-establishment of the gut microbiome
following bowel cleansing and colonoscopy.
Long-term effects in the study will be assessed 10 years
after recruitment is completed. This will include an in-
vestigation of incidence and mortality of advanced colo-
rectal lesions.
Clinical data, biological sampling and questionnaires
Assessment of clinical data
As part of the BCSN [46], participants are contacted by
a study nurse prior to follow-up colonoscopy, to obtain
information on medical history. This includes prior
colonoscopies and CT colonographies, comorbidities,
drug use, gastrointestinal symptoms, smoking habits,
and body weight and height (Table 3). A variety of data
are collected in relation to the follow-up colonoscopy,
including screening outcomes (i.e. presence and clinico-
pathological characterization of detected lesions) and
characteristics relevant to the endoscopic procedure
(Table 3). For all lesions detected; size, location, appear-
ance, technique used for removal and tissue sampling,
and completeness of removal, are recorded. Both the
medical history data and data collected as part of the
follow-up colonoscopy, are entered into a dedicated
database by the responsible health care provider. A
complete overview of the data collected in the BCSN
trial can be found elsewhere [46].
Biological sampling and gut microbiome analysis
FIT sampling and storage Sampling kits for stool sam-
ple collection are mailed to the participants three times
during the study period, with the first sample being the
positive BCSN FIT sample. No restrictions on diet or
Table 1 Inclusion and exclusion criteria in the BCSN trial and
CRCbiome study
Inclusion criteria
BCSN Aged 50–74 years old in 2012
Resident in selected municipalities in South-East Norway
(Østfold, parts of Akershus and parts of Buskerud)
CRCbiome
FIT positive test (i.e. hemoglobin > 15 mcg/g feces) and
invited to a follow-up colonoscopy
Exclusion criteria
BCSNa Death
Moving out of the area
Reaching the upper age limit
Diagnosed with CRC
CRCbiome
Not attending screening colonoscopy
Low DNA concentration
Low sequencing yield (< 2 gigabases)
aExclusion criteria apply for individuals who died, moved out of the area, reached
the upper age limit, or were diagnosed with CRC before they were due
for invitation
Table 2 Main outcomes of the screening colonoscopy among
CRCbiome participants with preliminary distribution in
percentages as of November 2020
Colonoscopy result Percentagesa
FIT+, no colonoscopy 3.6
Group 1
Negative 11.2
Polyp without histologyb 2.4
Non neoplastic findings 18.2
Group 2
Non-advanced serrated lesionsc 6.4
Non-advanced adenomas (< 3) 23.6
Non-advanced adenomas (≥3) 8.4
Group 3




aAn extended version of this table, with colonoscopy result by FIT round, is shown
in Additional file 1 (Supplementary Table 2). In cases of multiple findings,
participants are allocated to the most severe group. Numbers will therefore add
up to 100%
bPolyps lost during colonoscopy or where the endoscopist considers biopsy
unnescessary, for example hyperplastic polyps in the rectum
cIncludes hyperplastic polyps with size < 10 mm and sessile serrated lesions
without dysplasia and size < 10 mm
dDefined as any serrated lesions with size ≥ 10 mm or dysplasia
eDefined as any adenoma with either villous histology (≥25% villous
components), high-grade dysplasia or polyp size greater than or equal to
10 mm [52]
fDefined as presence of adenocarcinoma arising from the colon or rectum.
Collectively, advanced adenoma or CRC are referred to as advanced
neoplasia [52]
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medication use are required prior to sampling. Stool is
collected using plastic sticks, which collect about 10 mg
stool. The stool is then stored in 2 ml of buffer contain-
ing HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfo-
nic acid), BSA (Bovine serum albumin) and sodium
azide. Samples are then packed in padded envelopes and
returned by mail to a laboratory at Oslo University Hos-
pital for analysis and further storage at − 80 °C. Shipping
time is estimated to 3–10 days. Immunochemical testing
for blood in feces is performed continuously using the
OC-Sensor Diana (Eiken Chemical, Tokyo, Japan) as
samples are received at the laboratory.
DNA extraction We have shown that fecal matter col-
lected in the FIT sampling procedure yields comparable
microbial diversity and composition to fresh frozen stool
samples [53].
Thawed samples are transferred to three 500 ml ali-
quots from the sampling bottle using a blood sampling
needle (Vacuette) perforating the plastic lid. Samples are
stored at − 80 °C until further processing.
Extraction of DNA is carried out using the QIAsymph-
ony automated extraction system, using the QIAsymph-
ony DSP Virus/Pathogen Midikit (Qiagen), after an off-
board lysis protocol with some modifications. Each sam-
ple is lysed with bead-beating: a 500 μl sample aliquot is
transferred to a Lysing Matrix E tube (MP Biomedicals)
and mixed with 700 μl phosphate-buffered saline (PBS)
buffer. The mixture is then shaken at 6.5 m/s for 45 s.
After the bead-beating, 800 μl of the sample is mixed
with 1055 μl of off-board lysis buffer (proteinase K, ATL
buffer, ACL buffer and nuclease-free water) as recom-
mended by Qiagen. The sample is incubated at 68 °C for
15 min for lysis. Nucleic acid purification is performed
on the QIAsymphony extraction robot using the Com-
plex800_OBL_CR22796_ID 3489 protocol, a modified
version of the Complex800_OBL_V4_DSP protocol.
Purified DNA is eluted in 60 μl AVE-buffer (Qiagen).
DNA purity is assessed using a Nanodrop2000 (Thermo
Fisher Scientific, USA), and the concentration is mea-
sured by Qubit (Thermo Fisher Scientific, USA).
Metagenome sequencing Libraries for metagenome se-
quencing are prepared from extracted DNA at the se-
quencing laboratory of the Institute for Molecular
Medicine Finland FIMM Technology Centre, University
of Helsinki (P.O. Box 20, University of Helsinki, Finland)
using Illumina sequencing, with the aim of producing 3
gigabases of DNA sequence per sample.
In details, 29 μl of extracted DNA is purified and con-
centrated by adding an equal volume of AMPure XP
(Beckman Coulter Life Sciences, Indianapolis, IN, USA).
Purification is then performed as per the manufacturer’s
instructions. The purified samples are eluted to 17 μl of
10 mM Tris-HCl, pH 8.5, and DNA concentrations are
determined by Quant-iT PicoGreen dsDNA Assay Kit
(Thermo Fisher Scientific, Waltham, MA, USA). The
samples are normalized to a maximum concentration of
3.3 ng/μl, resulting in DNA inputs of 25 ng or less.
Sequencing libraries are prepared according to the
Nextera DNA Flex Library Prep Reference Guide (v07)
(Illumina, San Diego, CA, USA), with the exception that
the reaction volumes are scaled down to ¼ of the proto-
col volumes. The libraries are amplified according to the
protocol with 7 PCR cycles. All the library preparation
steps are performed on a Microlab STARlet (Hamilton
Company, Reno, NV, USA) and Biomek NXP (Beckman
Coulter Life Sciences, Indianapolis, IN, USA) liquid han-
dlers running custom scripts.
DNA concentrations of the finished libraries are deter-
mined with Quant-iT PicoGreen dsDNA Assay. Libraries
are combined into pools containing 240 libraries with
4.5 ng of each library using Echo 525 Acoustic Liquid
Handler (Beckman Coulter Life Sciences, Indianapolis,
IN, USA). Library pools are size-selected to a fragment
size range between 650 and 900 bp using BluePippin
(Sage Science Beverly, MA, USA).
Sequencing is performed with the Illumina NovaSeq
system using S4 flow cells with lane divider (Illumina, San
Diego, CA, USA). Each pool is sequenced on a single lane.
Read length for the paired-end run is 2 × 151 bp.
Processing and analysis of sequencing data Sequen-
cing data are transferred to a platform for secure storage
and analysis of sensitive research-related data at the Uni-
versity of Oslo [54]. The analysis of metagenomic se-
quencing data is handled in a uniform manner using a
customizable workflow manager [55]. To establish a
quality-filtered dataset, standard filters are applied: se-
quences corresponding to adapters used in library prep-
aration, being of low quality [56] and those mapping to
the human genome [57], with subsequent quality control
of filtered sequencing reads [58].
Taxonomic classification and determination of micro-
bial gene content, including functional annotation (e.g.
using gene ontology and KEGG databases) will be per-
formed using publicly available tools. Abundance mea-
sures will be used to calculate taxonomic and functional
alpha and beta diversity, as well as serving as input for ma-
chine learning approaches aimed at producing classifiers
for high-risk individuals in a data-driven manner. Further
metagenome-derived measures may include identification
of metagenome-assembled genomes, strain-level analysis
and description of the gut virome.
Questionnaires
Two questionnaires are used to collect data on diet, life-
style and demographic information; a food frequency
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questionnaire (FFQ) and a general lifestyle and demo-
graphics questionnaire (LDQ). Self-reported dates of ques-
tionnaire completion are registered in the project
database. Returned questionnaires are reviewed manually
before scanning and further processing. In cases of low-
quality data, participants are contacted for clarification.
Assessment of dietary intake Dietary intake is assessed
using a semiquantitative, 14-page FFQ, designed to as-
sess the habitual diet during the preceding year. The
questionnaire is a modified version of an FFQ developed
and validated by the Department of Nutrition, University
of Oslo [59–64]. The questionnaire has been validated
for both energy intake [59–61], intake of macro and
micronutrients [59, 61, 64], as well as selected food
items and groups [61–64]. The questionnaire includes
23 main questions, covering a total of 256 food items, as
well as a free-text field for entries of food items not cov-
ered by the questionnaire. For each food item (except
one on preferred types of fat for cooking), participants
are asked to record frequency of consumption, ranging
from never/seldom to several times a day, and/or
amount, typically as portion size given in various house-
hold units (e.g. deciliters, glasses, cups, spoons). In total,
there are 249 questions on frequency, 204 on portion
size, one on preferences and nine other, mostly related
to meal patterns (Additional file 1, supplementary
Table 1).
As with any dietary assessment method, the FFQ is
prone to errors due to inaccurate reporting and missing
answers. Therefore, to mitigate such errors, a standard-
ized framework for how to review and evaluate FFQ
quality has been developed. A detailed overview of the
framework is given in Additinoal file 2, supplementary
Fig. 1. In brief, incoming FFQs are reviewed by trained
personnel according to a set of predefined criteria. Scan-
ning of questionnaires is performed using the Cardiff
TeleForm program (Datascan, Oslo, Norway). The diet-
ary calculation system KBS (short for “Kostberegnings-
system”), developed at the Department of Nutrition,
University of Oslo, is used to calculate food and nutrient
intake. The latest version of the food database (i.e. AE-
18 or newer) will be used, which is largely based on the
Norwegian Food Composition Table [65]. In line with
common practice in nutrition studies, missing answers
are imputed as zero intake [61, 63, 66, 67] and observa-
tions with extreme energy intake levels in both the
upper and lower range will be excluded [68].
The main focus of the dietary analyses will be on foods
and drinks linked to the risk of CRC and its precursor
lesions, including intakes of alcohol, red and processed
meat, wholegrains, foods containing dietary fiber, dairy
products and calcium supplements [69]. Dietary intake
will also be studied holistically by employing various
dietary indices such as the 2018 World Cancer Research
Fund/American Institute for Cancer Research (WCRF/
AICR) index for adherence to cancer prevention recom-
mendations [70].
Assessment of lifestyle and demographic data Life-
style and demographic data are assessed using a four
page questionnaire based on questions used in previous
national surveys [71, 72]. Prior to the study start, the
questionnaire was piloted in a targeted population and
adjusted based on feedback from pilot study participants.
The questionnaire has ten main questions covering
demographic factors (national background, education,
occupation and marital status), diagnosis of CRC among
first-degree relatives, presence of chronic bowel disor-
ders and food intolerances, removal of the appendix,
mode of delivery at birth, smoking and snus (i.e. smoke-
less tobacco) habits, recent use of medications, the past
years’ physical activity level and use of regular and cul-
tured milk, which is not completely covered in the FFQ
(see Table 3 for a detailed overview). In the questions
concerning smoking and snus habits, participants are
asked to recall their current habits, including the daily
number of cigarettes/snus portions, as well as years since
possible cessation and total years of use. Questionnaires
are scanned and processed using the Cardiff TeleForm
program (InfoShare, Oslo, Norway).
Registry data
Data collected in the CRCbiome study will be linked to
national registries, including the Norwegian Prescription
Database and the Cancer Registry of Norway, using per-
sonal identification numbers. Complete data linkages
will be undertaken twice during active follow-up: after
all participants have completed baseline and diagnostic
information from follow-up colonoscopies is available,
and then after the one-year follow-up is completed. In
addition, linkage to the Cancer Registry of Norway will
be performed at least once during the 10 year follow-up
period.
Norwegian prescription database
The Norwegian Prescription Database [73] will be used
to obtain information on medication history prior to
CRC screening, and during the first year of follow-up.
The registry contains data on all medications prescribed
to Norwegian citizens since 2004. Prescription drugs are
categorized according to the Anatomical Therapeutic
Chemical (ATC) system, a hierarchical classification sys-
tem developed by the WHO [74, 75]. For each drug, the
number of packages dispensed, the number of defined
daily doses (DDD), the prescription category, and the
date of dispensing are registered.
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Linkage to the Norwegian Prescription Database en-
ables an in-depth analysis of associations between drug
use, the gut microbiome and advanced colorectal lesions.
Initially, we will perform drug-wide association analyses
to screen for potential associations, adjusting for key co-
variates. Detected associations will then be examined in
detail, including a more refined categorization of drug
variables, robust covariate adjustments as well as the
analysis of timing and dose-response relations. Prescrip-
tion histories will also be used as a proxy for life-long
burden of chronic diseases. To examine the representa-
tiveness of the drug profiles discoverd in the CRCbiome
study, a randomly selected control group drawn from
the National Population Registry, might be included.
Cancer registry of Norway
Information on clinicopathological characteristics, can-
cer therapy, as well as outcomes assessed as part of pas-
sive follow-up, will be obtained from the Cancer
Registry of Norway [76]. The Cancer Registry of Norway
has recorded incident cancer cases on a nationwide basis
since 1953 and has been shown to have accurate and al-
most complete ascertainment of cases (98.8% for the
registration period 2001–2005) [77]. According to recent
estimates, about 93% of all cancer cases and ≥ 95% of
cancers in the colon and rectum are morphologically
verified [48]. Cancer diagnoses are recorded using the
International Classification of Diseases, version 10 (ICD-
10). Mortality data in the registry are obtained from the
Cause of Death Registry and coded using the same ICD-
10 categories as for the incidence data.
Data processing and management
To facilitate project administration, including recruit-
ment and follow-up of participants, custom software has
been developed. This application communicates with
two project specific databases (i.e. the BCSN and
CRCbiome databases). Only authorized data manager
personnel have complete access to the datasets. A sim-
plified version of the data generation process is depicted
in Fig. 2.
In line with common practice for linkage with national
registries [78], linked data will receive unique ID num-
bers specific to the particular project. Linkage of re-
search data will be performed by the data controller. For
the metagenome data, which due to its size cannot be
Fig. 2 Simplified version of the data generation process in CRCbiome. The figure is created based on free images from Servier Medical Art
(Creative Commons Attribution Liscence, creativecommons.org/liscences/by/3.0/) and Stockio (https://www.stockio.com/)
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transferred using ordinary methods, linkage will be per-
formed in-house by an independent data manager with-
out access to other parts of the data than those strictly
necessary for linkage.
All data collected in the CRCbiome study will be
stored and analyzed at a platform for secure handling of
sensitive research-related data, operated by the Univer-
sity of Oslo [54]. Access to research data for external in-
vestigators, or use outside of the current protocol, will
require approval from the Norwegian Regional Commit-
tee for Medical and Health Research Ethics and a data
access committee (information available on the project
web site [79]). Research data are not openly available be-
cause of the principles and conditions set out in articles
6 [1] (e) and 9 [2] (j) of the General Data Protection
Regulation (GDPR).
Statistical analyses and sample size considerations
The number of participants to include was chosen with
the aim of providing adequate power for the develop-
ment of a highly sensitive classification algorithm via
data-driven analyses of gut metagenomes that will accur-
ately identify FIT-positive individuals in need of clinical
intervention.
The classifier will be trained using counts of taxo-
nomic units, signature and genes categorized according
to gene ontology or pathway membership from meta-
genomes, FFQ, demographic and lifestyle data as input
variables, and advanced colorectal lesions as outcome
(i.e. group group 3 and group 4, Table 2). The CRC risk
classification will be done using machine learning algo-
rithms suited to metagenome data, such as lasso regres-
sion [80], support-vector machines [81], random forests
[82], multi-layer perception neural networks [83] and
scalable tree boosting [84] algorithms. Evaluation of the
classifier will be conducted in a leave-out test set. As
outlined below, we believe that with sufficient sample
size, development of a classifier with a sensitivity of 0.95
is achievable in the training set, being within the range
of published reports [30, 33].
Interpretation of the classifier will be sought by post
hoc analysis, quantifing the importance of individual fea-
tures (taxa, genes and pathways) in making predictions.
Stratified analyses will be done to evaluate the classifier
within different subgroups of the population (e.g. by age
group, sex and screening center).
With a projected classifier sensitivity of 0.95 and a
minimally acceptable sensitivity of 0.8, at 80% power and
95% confidence level, 50 participants with advanced
colorectal lesions are required in the test set [85]. Classi-
fier specificity in the setting of FIT-positive individuals
will have a lower requirement, and we therefore set the
expected classifier specificity to 0.75 and a minimally ac-
ceptable specificity of 0.6, thus requiring 100 participants
with normal findings in the test set. Based on initial re-
cruitment, we expect a participation rate of 58%, with
26% of participants having findings of advanced lesions
or CRC (Table 2). By inviting 2700 FIT-positive BCSN
participants, and splitting the training and test sets 80/
20, a projected number of 1253 and 313 participants will
constitute the training and test sets, respectively, which
will include adequate numbers of participants with both
advanced colorectal lesions and normal findings in the
test set. With this sample size, we will also be able to
perform stratified analyses. The machine learning ana-
lyses will be complemented by various multivariate re-
gression analyses, stratified by the covariates outlined
above.
Discussion
CRC remains a major public health challenge with sub-
stantial personal and societal costs [22]. Screening is an
effective measure to reduce disease burden [22]. How-
ever, current screening methods suffer from limitations,
limiting the number of preventable cases. Innovative use
of currently available methods represents a promising
avenue for improvements in CRC prevention [22]. The
current study is designed to contribute to the develop-
ment of microbial biomarkers, using metagenome se-
quencing and comprehensive questionnaire and registry
data for improved detection of advanced lesions and
CRC in a FIT-positive population. The CRCbiome study
is unique in that it uses data from the screening popula-
tion to develop relevant biomarkers.
The idea of using microbial biomarkers to increase the
performance of CRC screening has received increased
attention with the adoption of high-throughput
characterization of the gut microbiome. Ideally, combin-
ing microbial biomarkers with FIT testing could achieve
the sensitivity of direct visualization methods and the
uptake of non-invasive fecal tests. Several studies have
demonstrated improved ability to discriminate individ-
uals with healthy colons from those with advanced neo-
plasia when adding microbial biomarkers in the
prediction model, more so for carcinoma (area under
the curve (AUC) of 0.87–0.97 [30, 33, 34]) than aden-
oma (AUC of 0.76 [33]). Despite great promise, these
studies have typically been limited by small sample sizes
[30, 32–34], cross-sectional designs [30–34], use of sub-
optimal or low-resolution methods to study the gut-
microbiome [30–33] and lack of data on important con-
founders [30–34]. The CRCbiome study seeks to address
several of these shortcomings.
Major strengths of the CRCbiome study include its
large sample size and prospective nature, use of state of
the art methodology for studying the gut microbiome
and access to detailed information on likely confounders
of the relationship between the gut-microbiome and
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advanced colorectal lesions. A further strength of the
study is in its organization and logistics structure, being
nested within the BCSN. The immediate availability of
clinically verified outcome data, via follow-up colonos-
copies and cancer registry data, allow for prospective in-
vestigations on multiple outcomes relevant to the
screening population (e.g. polyp recurrence). Access to
comprehensive high-quality data on diet and lifestyle, in-
cluding complete prescription histories, also enables the
investigation of the predictive performance of more
broad classifiers, laying the ground for personalized
screening strategies, including risk-stratified approaches.
With a study population solely consisting of FIT positive
participants, the projected number of individuals with
high-risk lesions or CRC is relatively high (about 409
(26%), group 3 and 4, Table 2), thereby increasing the
power to achieve accurate classification of advanced colo-
rectal neoplasms. Still, whether findings in this population
extends to cases missed by FIT testing is unknown.
Collection of follow-up samples at 2 and 12-months
post colonoscopy represents an extension of the cross-
sectional design of most prior studies, shedding light on
the development of the gut microbiome following colon-
oscopy with or without removal of CRC precursor le-
sions. While there are examples of shifts in microbial
profiles following colonoscopy, the gut microbiome typ-
ically reverts to the initial state within weeks [86]. Devia-
tions from re-establishment of the gut microbiome both
in the medium and long term have the potential for
causal interpretations.
The study also has some limitations. Exclusive selection
of FIT positive participants may limit the generalizability
of the findings to those with bleeding neoplastic lesions.
Consequently, improvements in diagnostic performance
may be limited to specificity, and thus the ability to cor-
rectly classify healthy individuals. However, since lesions
tend to bleed intermittently [87] and the study aims to
identify potential causal pathways, we consider it likely
that the identified biomarker also may have improved sen-
sitivity in the screening population as a whole.
A further limitation is the lack of information on fecal
metrics such as the Bristol stool scale, which has been
shown to be an important determinant of microbiota rich-
ness and variance [88]. However, variation in microbiome
profile due to stool consistency could likely be explored by
use of gastrointestinal symptoms as a surrogate, data on
which is available in the BCSN database.
Lastly, lack of follow-up data on diet and lifestyle may
complicate the interpretation of microbial changes follow-
ing colonoscopy. Even though prior studies in comparable
study populations show that potential changes in diet and
lifestyle following screening are modest [89, 90], caution
in interpretation of follow-up samples is warranted.
The CRCbiome study represents a valuable source of
data for further research. An example is access to
complete prescription histories from the Norwegian Pre-
scription Database that enables in-depth analyses of as-
sociations between a broad range of medications,
microbial features and neoplasia risk, both during short
and long-term follow-up. The fecal samples collected are
also biobanked and can be used for other purposes be-
side the study aims of the current protocol. For instance,
in addition to metagenome sequencing, the fecal samples
can potentially be used for other omics analyses, such as
transcriptome and metabolome analysis. All tissue speci-
mens removed during colonoscopy are also available to
the project, enabling in-depth molecular profiling.
The integration of a microbiome-based biomarker into
national CRC screening programs is a long-term process,
requiring many steps before enabling full implemtation.
Ideally, the discovery phase will lead to the identification
of a few selected features that will predict the occcurence
of advanced colorectal lesions with high accuracy. These
could then be combined by means of a biomarker panel
for the development of a rapid test, which, following rigor-
ous validation and testing, has the potential of being inte-
grated into screening programs. The cost-effectivness of
adding a microbial biomarker to the FIT test should be
carefully evaluated before implementation.
Conclusion
The CRCbiome study investigates the role of the gut
microbiome, and its interactions with host factors, diet
and lifestyle, in early stage colorectal carcinogenesis. In-
formation obtained from this project will guide the de-
velopment of a microbial biomarker for accurate
detection of advanced colorectal lesions. By performing
biomarker discovery within a screening population, the
generalizability of the findings to future screening co-
horts is likely to be high.
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